Leállítva1/2. fázis
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
A legfontosabb adatok
- Ki végzi
- BioMimetix JV, LLC
- Hol
- Detroit, Durham, Lexington és Seattle (Egyesült Államok)Mind a 4 helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1/2. fázis
- Résztvevők
- 35 fő vett részt
- Kezdés
- 2018. okt. 4.
- Befejezés
- 2024. ápr. 15.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- BMX-001
- Whole Brain Radiation Therapy
- A regiszteradat frissítve
- 2024. április 18.
- Miért állt le
- Cessation of grant funding
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Subjects must have histologically confirmed diagnosis of a non-small cell lung cancer, breast cancer, melanoma or renal cell cancer primary
- Subjects must have >5 contrast-enhancing lesions, never previously treated with SRS and/or surgical resection, on a contrast-enhanced T1-weighted brain MRI performed within two weeks of enrollment, with at least one lesion >0.5cm in greatest dimension
- Physical examination by a radiation oncologist or medical oncologist within 14 days of the start of WBRT
- Plan to be treated with WBRT to a dose of 30 Gy in 10 fractions
- Age * 18 years
- Karnofsky Performance Status (KPS) ≥ 70
- Hemoglobin ≥ 9.0 g/dl, ANC ≥ 1,500 cells/*l, platelets ≥ 125,000 cells/*l
- Serum creatinine ≤ 1.5 mg/dl, serum SGOT and bilirubin ≤ 1.5 times upper limit of normal
- Signed informed consent approved by the Institutional Review Board
- If sexually active, patients must agree to use appropriate contraceptive measures for the duration of the study and for 6 months afterwards as stated in the informed consent
- Able to provide study specific informed consent
- Willing to follow study procedures, complete QOL questionnaires and neurocognitive testing as described in the protocol
- Negative serum pregnancy test for women of child bearing potential within 48 hours of first dose of BMX
Ki nem vehet részt
- Active infection requiring IV antibiotics 7 days before enrollment
- Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure
- Subjects receiving prohibited medications listed in Section 6.4.2 of this protocol are not eligible. Subjects who can safely stop taking a prohibited medication at least 7 days prior to the first dose of BMX may participate at the discretion of the treating physician
- Prior surgical resection for brain metastases and/or stereotactic radiosurgery for up to 5 brain metastases in total are permitted if performed at least 1 month prior to planned WBRT under this protocol
- Prior whole brain radiation therapy
- Hypertension requiring 3 or more anti-hypertensive medications to control
- History of syncope within the last 6 months
- Known hypersensitivity to compounds of similar chemical composition to BMX-001
- Patients with diffuse leptomeningeal disease (carcinomatous meningitis)
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 milliseconds (ms) (CTCAE grade 1)
- A history of additional risk factors for TdP (e.g., congestive heart failure, hypokalemia, known family history of Long QT Syndrome)
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
- Women who are breast feeding
Helyszínek itt: Egyesült Államok
- Henry Ford HospitalDetroit, Egyesült Államok
- Duke Cancer InstituteDurham, Egyesült Államok
- University of KentuckyLexington, Egyesült Államok
- University of WashingtonSeattle, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2 clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain metastases (MBM) undergoing whole brain radiation therapy (WBRT). Preliminary studies have demonstrated that BMX-001 provides protection of normal tissues from radiation-induced injury and augments tumor growth inhibition.
A vizsgálat 2 csoportja
- WBRT + BMX-001Már használt kezelés, összehasonlításként
Whole brain radiation therapy in combination with BMX-001 (subcutaneous injection of 28 mg loading dose, followed by subsequent 14 mg twice per week for 2 weeks).
Kezelés: BMX-001 és Whole Brain Radiation Therapy
- Whole Brain Radiation TherapyNincs vizsgálati kezelés, összehasonlításként
Whole brain radiation therapy per standard of care.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Safety Lead-In/Randomized Phase 2 Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
- A regiszteradat frissítve
- 2024. április 18.